Protein kinase inhibitor

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook 2019-2023 with Bayer, Gilead Sciences, Novartis, TG Therapeutics, and Verastem Leading the Competition - ResearchAndMarkets.com

Retrieved on: 
Monday, July 29, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Medicine, Cancer, Clinical medicine, Oncology, Drug discovery, Phosphoinositide 3-kinase inhibitor, Antineoplastic drugs, Signal transduction, Chronic lymphocytic leukemia, Phosphoinositide 3-kinase, Protein kinase inhibitor, Tumors of the hematopoietic and lymphoid tissues

The "Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • Although many approved therapies are available for various types of blood cancer, the market still witnesses a huge unmet need.
  • The phosphoinositide 3-kinase inhibitors market analysis considers sales from chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL), and other indications.
  • With the presence of few major players, the global phosphoinositide 3-kinase inhibitors market is concentrated.

Entrectinib (Roche/Chugai/Nerviano): Global Drug Overview & Outlook with Sales for Non-small Cell Lung Cancer (NSCLC) by Country 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Health, Oncology, Chemical compounds, Tyrosine kinase receptors, Organic compounds, Entrectinib, ROS1, Anaplastic lymphoma kinase, Trk receptor, Tropomyosin receptor kinase B, Protein kinase inhibitor, Tyrosine kinase, Oncogene, Kinase

Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins.

Key Points: 
  • Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins.
  • Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
  • However, mutations or molecular alterations can result in overactivity, setting off a signal cascade that drives uncontrolled proliferation.
  • In vivo models of entrectinib in TrkB expressing neuroblastoma cells suggest that the drug may enhance the efficacy of conventional chemotherapy.

Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) Overview 2019: An Oral Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1), VEGFR-2, & VEGFR-3

Retrieved on: 
Wednesday, June 26, 2019
Branches of biology, Tyrosine kinase receptors, Cell signaling, Cell biology, Growth factors, Tyrosine kinase inhibitors, Angiology, Proteins, VEGF receptor, Vascular endothelial growth factor, Kinase insert domain receptor, Protein kinase inhibitor

DUBLIN, June 26, 2019 /PRNewswire/ -- The "Fotivda" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 26, 2019 /PRNewswire/ -- The "Fotivda" report has been added to ResearchAndMarkets.com's offering.
  • Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3.
  • Inhibition of VEGF signaling in order to prevent angiogenesis is a well-established strategy across many tumor types; however, Fotivda's potency, selectivity, and long half-life are hypothesized to improve the drug's efficacy and safety in comparison to its predecessors.
  • In the US, the initial New Drug Application, also based on the TIVO-1 clinical trial data, was met with a complete response letter from the US Food and Drug Administration (FDA).

Market Spotlight to 2026: Waldenstrom Macroglobulinemia (WM) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 19, 2019
Professional services, Consulting, Chemical compounds, Organic compounds, Tyrosine kinase inhibitors, Lymphoma, Waldenström's macroglobulinemia, Clinical medicine, Ibrutinib, Celgene, Protein kinase inhibitor

The "Market Spotlight: Waldenstrm Macroglobulinemia (WM)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Waldenstrm Macroglobulinemia (WM)" report has been added to ResearchAndMarkets.com's offering.
  • This report covers the Waldenstrom Macroglobulinemia market, comprising key marketed and pipeline drugs, probability of success, clinical trials, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • Imbruvica, a small molecule tyrosine kinase inhibitor, is the only drug approved by the FDA for WM.
  • Takeda also leads industry sponsors with the highest number of clinical trials for WM, followed by Celgene.

The BRAF kinase inhibitors market will register a CAGR of over 8% by 2023

Retrieved on: 
Tuesday, June 18, 2019
Clinical medicine, Cancer, Medicine, Protein kinase inhibitor, BRAF, Melanoma, Non-small-cell lung carcinoma, MEK inhibitor, Dabrafenib

Our analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.

Key Points: 
  • Our analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.
  • Currently, BRAF kinase inhibitors are approved for some of the major cancers such as NSCLC, metastatic melanomas, and RCC.
  • Therefore, the strong prevalence of various cancer indications is driving the growth of the global BRAF kinase inhibitors market.
  • For the detailed list of factors that will drive and challenge the growth of the BRAF kinase inhibitors market during 2019-2023, view our report.

The BRAF kinase inhibitors market will register a CAGR of over 8% by 2023

Retrieved on: 
Tuesday, June 18, 2019
Clinical medicine, Cancer, Medicine, Protein kinase inhibitor, BRAF, Melanoma, Non-small-cell lung carcinoma, MEK inhibitor, Dabrafenib

Our analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.

Key Points: 
  • Our analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.
  • Currently, BRAF kinase inhibitors are approved for some of the major cancers such as NSCLC, metastatic melanomas, and RCC.
  • Therefore, the strong prevalence of various cancer indications is driving the growth of the global BRAF kinase inhibitors market.
  • For the detailed list of factors that will drive and challenge the growth of the BRAF kinase inhibitors market during 2019-2023, view our report.

Targeted Cancer Therapeutics Market, 2025

Retrieved on: 
Wednesday, June 5, 2019
Medicine, Clinical medicine, Branches of biology, Tyrosine kinase receptors, Antineoplastic drugs, Cancer treatments, Oncology, Drugs, Targeted therapy, Protein kinase inhibitor, Epidermal growth factor receptor, Treatment of cancer

DUBLIN, June 5, 2019 /PRNewswire/ -- The "The 2019 Worldwide Market for Targeted Cancer Therapeutics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 5, 2019 /PRNewswire/ -- The "The 2019 Worldwide Market for Targeted Cancer Therapeutics" report has been added to ResearchAndMarkets.com's offering.
  • The 2019 Worldwide Market for Targeted Cancer Therapeutics focuses on the expanding area of targeted therapies and includes current products available and discusses some of the most exciting developments in progress.
  • Cancer treatment markets have been slower to develop in Latin American markets, with targeted therapies often secondary to traditional chemotherapy or hormone therapy.
  • The 2019 Worldwide Market for Targeted Cancer Therapeutics provides regional market overviews, encompassing United States and Canada; Europe, Middle East and Africa (EMEA); Asia Pacific; and Latin America:
    This report covers targeted cancer therapies that do at least one of the following:
    Carry toxins to the cancer cells to kill them, but not normal cells
    This report on the targeted cancer therapeutics market specifically focuses on five leading segments of targeted therapies - monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, CDK inhibitors, and proteasome inhibitors - providing information on a global level, including:
    Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions) (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)
    Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
    Monoclonal Antibodies in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
    Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
    Tyrosine Kinase Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
    Angiogenesis Inhibitors in Cancer Therapy (Trade Name, Biological Name, Indication[s])
    CDK Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
    Proteasome Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
    Other Targeted Cancer Therapies (Classification, Trade Name, Biological Name, Target, Indication[s])
    The report also provides specific information by type and by target on a global level for the monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) segments, including:
    Development of the mAb Cancer Treatment Market, 2010-2025 (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung, Renal, Others)
    Monoclonal Antibody Market by Cancer Type, 2018 and 2025 ($ millions) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
    Monoclonal Antibody Market Distribution by Indication, 2025 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
    Development of the TKI Cancer Treatment Market, 2010-2025 (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
    TKI Market by Cancer Indication, 2018 and 2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
    TKI Market Distribution by Cancer Indication, 2018 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
    TKI Market Distribution by Cancer Indication, 2025 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
    Cancer Monoclonal Antibody Market by Target, 2018 and Forecast 2025 ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
    Cancer Monoclonal Antibody Market Distribution by Target, 2018 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
    Cancer Monoclonal Antibody Market Distribution by Target, 2025 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
    Cancer TKI Market by Target, 2018 and Forecast 2025 ($ millions) (Single Target: ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
    TKI Market Distribution by Target, 2018 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
    TKI Market Distribution by Target, 2025 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)

Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting

Retrieved on: 
Friday, May 31, 2019
Chemical compounds, Organic compounds, Lung cancer, Pyrimidines, Ethers, Quinazolines, Epidermal growth factor receptor, Osimertinib, Tyrosine-kinase inhibitor, Daiichi Sankyo, Protein kinase inhibitor, T790M

All 16 patients had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI), including 15 with osimertinib.

Key Points: 
  • All 16 patients had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI), including 15 with osimertinib.
  • A total of 16 patients remained on treatment at the time of data cut-off on February 25, 2019.
  • Preliminary safety datain 23 evaluable patients showed a manageable safety profile for U3-1402 with median treatment exposure of 105 days.
  • Part of the investigational ADC Franchise of the Daiichi Sankyo Cancer Enterprise, U3-1402 is an investigational and potential first-in-class HER3 targeting ADC.

Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting

Retrieved on: 
Friday, May 31, 2019
Chemical compounds, Organic compounds, Lung cancer, Pyrimidines, Ethers, Quinazolines, Epidermal growth factor receptor, Osimertinib, Tyrosine-kinase inhibitor, Daiichi Sankyo, Protein kinase inhibitor, T790M

All 16 patients had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI), including 15 with osimertinib.

Key Points: 
  • All 16 patients had received prior treatment with an EGFR tyrosine kinase inhibitor (TKI), including 15 with osimertinib.
  • A total of 16 patients remained on treatment at the time of data cut-off on February 25, 2019.
  • Preliminary safety datain 23 evaluable patients showed a manageable safety profile for U3-1402 with median treatment exposure of 105 days.
  • Part of the investigational ADC Franchise of the Daiichi Sankyo Cancer Enterprise, U3-1402 is an investigational and potential first-in-class HER3 targeting ADC.

Global BRAF Kinase Inhibitors Market 2019-2023 | High Target Affinity and Specificity of BRAF Kinase Inhibitors to Boost Growth | Technavio

Retrieved on: 
Friday, May 24, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Chemical compounds, Clinical medicine, Organic compounds, Cancer treatments, B-Raf inhibitor, Sulfonamides, Chloroarenes, Tyrosine kinase inhibitors, BRAF, Vemurafenib, Protein kinase inhibitor, Dabrafenib

View the full release here: https://www.businesswire.com/news/home/20190524005082/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190524005082/en/
    Technavio has published a new market research report on the global BRAF kinase inhibitors market from 2019-2023.
  • Thus, such substantial benefits from BRAF kinase inhibitors will help support the growth of the global BRAF Kinase inhibitors market during the forecast period.
  • This global BRAF kinase inhibitors market 2019-2023 research report also analyzes other significant trends and market drivers that will affect market growth over 2019-2023.
  • Global BRAF kinase inhibitors market: Segmentation analysis
    This market research report segments the global BRAF kinase inhibitors market by product (dabrafenib, sorafenib, vemurafenib, and encorafenib) and geographical regions (North America, Europe, Asia, ROW).